Targeting TPL2 in RAS-mutated cancers

— Technology Description

Researchers in Kian-Huat Lim’s lab at Washington University have developed a therapeutic strategy to target TPL2 in RAS-mutated cancers, which should work synergistically with chemotherapy and radiation. As TPL2 (MAP3K8) is necessary for upstream activation of both MAP…

Create a Collection
Creating...